PD-(L)1 x VEGF bispecifics prove a big draw.
ApexOnco Front Page
Recent articles
The company, apparently unbothered by Enhertu, is starting a new HER2 x HER2 phase 3.
The latest first-in-human trial initiations include projects licensed in by Gilead and Context.
In ALK-positive NSCLC Nuvalent is starting a first-line phase 3, but the ROS1 path could be easier.
In first-line breast cancer vepdegestrant will be combined with Pfizer’s investigational CDK4 inhibitor atirmociclib.
The UK company buys IRDx for $1bn.
Scorpion's STX-478 becomes at least the third shot Lilly has taken at PI3Kα.
The latest B7-H4 ADC shows activity only in biomarker-positive patients.
